Shots:

• Lilly and Incyte reported that the US FDA has extended the review period of sNDA for baricitinib to treat adults with mod. to sev. atopic AD
• The FDA has extended the action date- allowing the time to review additional data analyses submitted by Lilly in response to recent information requests from the FDA. The PDUFA date has been extended 3 mos. to early Q3’21
• The companies are evaluating baricitinib in adult and pediatric patients with AD- AA- SLE- JIA- COVID-19 and also continues for RA

  Ref: PRNewswire | Image: The Straits Times